Equity Research Agricultural Chemicals

Should You Buy Mosaic Company (The) Stock in 2026?

By CirclFi Research Team · · 11/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Mosaic Company (The) (MOS) carries a solid Quality of Company rating of 7.3/10. Trading at $22.41, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 8 of 11 CirclFi valuation models project upside for Mosaic Company (The) (MOS) at $22.41 — the model consensus leans bullish, with a Quality Score of 7.3/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 8 of 11 models see upside — majority bullish
  • Quality Score: 7.3/10 — Strong — above-average quality
  • Value Trap Risk: —/100 — Not scored
  • Fair Value Range: $9.41 – $91.85 (876% spread)

Bullish Models

8 / 11

Bearish Models

3 / 11

Quality Score

7.3 /10

Strong — above-average quality

Value Trap Risk

/100
Not scored

Not scored

Model Consensus

11 /13
Active Models

Avg. confidence: 48%

Investment Thesis

The Bull Case

Target: $91.85 (+309.9% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Mosaic Company (The)'s quality score of 7.3/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation.
  • According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $22.41 and the composite fair value of $35.05 implies +56.4% upside potential.
  • According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model targets a fair value of $91.85 (+309.9%), anchoring the bull case with a methodology that incorporates probability-weighted cash flow scenarios.
  • Industry tailwind: automation and productivity gains could provide meaningful support for Mosaic Company (The)'s revenue and margin trajectory in the Agricultural Chemicals space.

The Bear Case

Target: $9.41 (-58.0%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model sees the stock as overvalued with a fair value of $9.41 (-58.0%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +367.9% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
  • Industry headwind: raw material cost inflation represents a meaningful risk for Mosaic Company (The) and its Agricultural Chemicals peers.

Peer Benchmarking

CF CF Industries Holdin
10.0
UAN CVR Partners, LP
9.1
BIOX Bioceres Crop Soluti
8.3
NTR Nutrien Ltd.
8.0
SNES SenesTech, Inc.
6.5

Valuation Divergence

Spread

876%

Fair Value Range

$9.41 – $91.85

A 876% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Bayesian DCF

$91.85 (+309.9%)

Most Bearish

Sentiment SOTP

$9.41 (-58.0%)

Key Risk Factors

Model Disagreement

876% spread signals high variance in projections.

Macro/Sector Risk

Agricultural Chemicals headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View MOS Data Page →

The Bottom Line

The balance of evidence tilts cautiously positive for Mosaic Company (The) at $22.41. 7 of 11 models support upside to $35.05, backed by a 7.3/10 quality foundation. This is a "lean into, not load up on" setup in our framework.

These are quantitative model outputs, not investment recommendations. Mosaic Company (The)'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy MOS stock right now?

Based on CirclFi's multi-model analysis, 8 of 11 models see upside for MOS at $22.41. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 7.3/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Mosaic Company (The)?

Key risks include: wide model disagreement (876% spread), signaling high uncertainty; general market and sector-specific risks affecting Agricultural Chemicals companies. Always diversify and consult a financial advisor.

How does MOS compare to its competitors?

Among Agricultural Chemicals peers, MOS holds a Quality Score of 7.3/10. Comparable companies include CF (QOC 10.0), UAN (QOC 9.1), BIOX (QOC 8.3). The relative ranking helps investors identify whether MOS offers better fundamental quality than alternatives in the same sector.

Is MOS a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. MOS's Quality Score of 7.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy MOS at?

CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $9.41 to $91.85. At $22.41, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for MOS.

View MOS Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →